Altamira Therapeutics Ltd. (CYTOF)
OTCMKTS
· Delayed Price · Currency is USD
0.0710
0.00 (0.00%)
May 13, 2025, 4:00 PM EDT
Altamira Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -8.46 | -4.31 | -27.78 | -18.71 | -9.27 | Upgrade
|
| Depreciation & Amortization | 0.13 | 0.13 | 0.12 | 0.08 | 0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 12.98 | 1.68 | - | Upgrade
|
| Loss (Gain) on Equity Investments | 0.77 | 0.04 | - | - | - | Upgrade
|
| Stock-Based Compensation | 0.53 | 0.42 | 0.36 | 1.32 | 0.42 | Upgrade
|
| Other Operating Activities | 0.88 | 1.52 | 1.5 | 0.28 | 3.01 | Upgrade
|
| Change in Accounts Receivable | -0.28 | 0.02 | -0.11 | -0.37 | 0.29 | Upgrade
|
| Change in Inventory | - | -0.36 | 0.87 | -0.92 | - | Upgrade
|
| Change in Accounts Payable | 0.06 | -3.67 | 1.32 | 3.22 | -0.2 | Upgrade
|
| Change in Other Net Operating Assets | 0.24 | -0.71 | 1.65 | -1.73 | 0.25 | Upgrade
|
| Operating Cash Flow | -6.11 | -12.81 | -9.09 | -15 | -5.47 | Upgrade
|
| Capital Expenditures | -0.1 | - | - | - | - | Upgrade
|
| Divestitures | 0 | 2.14 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | -2.24 | -3.65 | -2.62 | Upgrade
|
| Investment in Securities | -0.02 | -0.53 | - | -0.2 | - | Upgrade
|
| Other Investing Activities | 0 | 0 | 0 | - | 0 | Upgrade
|
| Investing Cash Flow | -0.12 | 1.61 | -2.24 | -3.84 | -2.62 | Upgrade
|
| Short-Term Debt Issued | - | 2.78 | 6.32 | - | 1.72 | Upgrade
|
| Total Debt Issued | - | 2.78 | 6.32 | - | 1.72 | Upgrade
|
| Short-Term Debt Repaid | - | -1.49 | - | -0.05 | - | Upgrade
|
| Long-Term Debt Repaid | -0.14 | -0.13 | -0.12 | -0.02 | - | Upgrade
|
| Total Debt Repaid | -0.14 | -1.61 | -0.12 | -0.08 | - | Upgrade
|
| Net Debt Issued (Repaid) | -0.14 | 1.17 | 6.2 | -0.08 | 1.72 | Upgrade
|
| Issuance of Common Stock | 7.37 | 11.69 | 4.15 | 7.51 | 18.17 | Upgrade
|
| Other Financing Activities | -0.73 | -1.04 | -0.06 | -0.18 | -0.72 | Upgrade
|
| Financing Cash Flow | 6.51 | 11.82 | 10.3 | 7.25 | 19.17 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.01 | 0.1 | -0.02 | 0.32 | 0.08 | Upgrade
|
| Net Cash Flow | 0.26 | 0.72 | -1.06 | -11.27 | 11.16 | Upgrade
|
| Free Cash Flow | -6.22 | -12.81 | -9.09 | -15 | -5.47 | Upgrade
|
| Free Cash Flow Per Share | -2.19 | -26.08 | -199.68 | -452.91 | -364.11 | Upgrade
|
| Cash Interest Paid | 0.01 | 0.17 | 0.02 | 0 | - | Upgrade
|
| Levered Free Cash Flow | -3.46 | -10.04 | -2.64 | -7.79 | -5.03 | Upgrade
|
| Unlevered Free Cash Flow | -3.44 | -9.32 | -2.05 | -7.78 | -4.94 | Upgrade
|
| Change in Net Working Capital | -0.28 | 5.34 | -3.78 | 0.56 | -0.97 | Upgrade
|
Updated Sep 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.